The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutralizing antibody responses against several different antigens.
This makes it possible to assess the strength of an individual's immune response to COVID-19.
Under the agreement, SphereDX will make the AditxtScore for COVID-19 available throughout its laboratory locations serving Kentucky, Ohio and Indiana.
The initiative is part of Aditxt's ongoing effort to expand its immune monitoring network nationwide.
SphereDX conducted a pilot program deploying the AditxtScore for COVID-19 in a group of area assisted living facilities.
Testing a total of 99 fully vaccinated residents ages 63 to 99, the results showed that 33.3% of the residents tested had a suboptimal immune response.
Of that group, 8.1% showed no discernable immune response to COVID-19.
The CDC has recommended that people with moderately to severely compromised immune systems receive an additional dose of the mRNA COVID-19 vaccine.
AditxtScore for COVID-19, which was first introduced in August 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual's immune response to multiple antigens associated with COVID-19.
This multiplex approach to capturing the full spectrum of biomarkers associated with COVID-19 delivers a highly detailed snapshot of an individual's immune response in a single test cycle.
It also includes the ability to measure neutralizing antibodies, the subset of virus-specific antibodies that block infection by interfering with cell entry of virus particles.
The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM and IgA isotopes, can provide clinicians with the data they need to understand the strength and quality of each individual's immune response to COVID-19.
AditxtScore for COVID-19 is offered through authorized channel partners.
This test is not for self-diagnosis and is not cleared or approved by the FDA.
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming.
Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT